Dipartimento Farmacochimico, Universita degli Studi di Bari, via Orabona 4, 70125, Bari, Italy.
Curr Drug Metab. 2011 Dec;12(10):985-8. doi: 10.2174/138920011798062292.
The pharmacological treatment of colorectal tumour leads to MultiDrug Resistance due to overexpression of several ABC transporters such as P-glycoprotein and some Multidrug associated Resistance Proteins (MRPs) that are able to efflux the chemotherapeutic agent out of the cell. A strategy to reverse MDR is the co-administration of antineoplastic agent with a P-glycoprotein inhibitor. These inhibitors are an useful tool for investigating, by PET, the expression and the activity of P-gp and MRPs that are overexpressed in chemoresistant colorectal tumor cells. In this review will be focused the aspect on P-gp and MRPs ligands employed as PET radiotracers considering their pharmacokinetic pharmacodynamic profile and their selectivity towards ABC transporters involved in chemoresistant cell of colorectal tumour.
结直肠肿瘤的药物治疗会导致多药耐药,这是由于多种 ABC 转运蛋白(如 P-糖蛋白和一些多药相关耐药蛋白(MRPs))的过度表达,这些蛋白能够将化疗药物从细胞内排出。逆转 MDR 的一种策略是将抗肿瘤药物与 P-糖蛋白抑制剂联合使用。这些抑制剂是通过 PET 研究 P-糖蛋白和 MRPs 表达和活性的有用工具,这些蛋白在耐药结直肠肿瘤细胞中过度表达。在本综述中,我们将重点关注作为 PET 放射性示踪剂的 P-糖蛋白和 MRPs 配体,考虑它们的药代动力学-药效学特征及其对涉及结直肠肿瘤耐药细胞的 ABC 转运蛋白的选择性。